PMID- 17998098
OWN - NLM
STAT- MEDLINE
DCOM- 20080306
LR  - 20161124
IS  - 0969-8051 (Print)
IS  - 0969-8051 (Linking)
VI  - 34
IP  - 8
DP  - 2007 Nov
TI  - Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose 
      transport are associated with resistance to 5FU in MCF7 cells in vitro.
PG  - 955-60
AB  - INTRODUCTION: Tumor refractoriness to chemotherapy is frequently due to the 
      acquisition of resistance. Resistant cells selected by exposure to chemotherapy 
      agents may exhibit differences in [18F]fluoro-2-deoxy-d-glucose (FDG) 
      incorporation, as compared with sensitive cells. METHODS: FDG incorporation, 
      hexokinase (HK) activity, glucose transport and ATP content were determined in 
      clones of 5-fluorouracil (5FU)-resistant MCF7 cells, established by long-term 
      exposure to increasing 5FU concentrations, and in parental MCF7 cells. RESULTS: 
      FDG incorporation was decreased in MCF7 cells resistant to 5FU; HK activity was 
      similar in the resistant and sensitive cells, while glucose transport was 
      increased, as compared with sensitive cells. Treatment of cells with the glucose 
      efflux inhibitor phloretin increased FDG incorporation to similar levels in the 
      resistant and sensitive cells. Analysis of microarray data demonstrated the 
      expression of GLUT1, 8 and 10 transporters in MCF7 cells. GLUT8 and 10 expression 
      was decreased in the resistant cells, while GLUT1 was only increased in cells 
      resistant to the lowest 5FU concentration. CONCLUSION: FDG incorporation in 
      5FU-resistant MCF7 cells is decreased, as compared with sensitive cells. Our 
      findings also suggest that this may be due to high rates of membrane glucose 
      transport in the resistant cells resulting in enhanced efflux of FDG. We believe 
      that this is the first demonstration that facilitative glucose transporters can 
      actually decrease the incorporation of FDG.
FAU - Smith, Tim A D
AU  - Smith TA
AD  - PET Unit, Department of Biomedical Physics, University of Aberdeen, Foresterhill, 
      Aberdeen AB25 2ZD, UK. t.smith@biomed.abdn.ac.uk
FAU - Sharma, Rituka I
AU  - Sharma RI
FAU - Wang, Weiguang G
AU  - Wang WG
FAU - Welch, Andy E
AU  - Welch AE
FAU - Schweiger, Lutz F
AU  - Schweiger LF
FAU - Collie-Duguid, Elaina S R
AU  - Collie-Duguid ES
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070919
PL  - United States
TA  - Nucl Med Biol
JT  - Nuclear medicine and biology
JID - 9304420
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - IY9XDZ35W2 (Glucose)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Biological Transport, Active/drug effects
MH  - Breast Neoplasms/*diagnostic imaging/*metabolism
MH  - Cell Line, Tumor
MH  - *Drug Resistance, Neoplasm
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Fluorouracil/*administration & dosage
MH  - Glucose/*metabolism
MH  - Humans
MH  - Metabolic Clearance Rate/drug effects
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals/pharmacokinetics
EDAT- 2007/11/14 09:00
MHDA- 2008/03/07 09:00
CRDT- 2007/11/14 09:00
PHST- 2007/06/29 00:00 [received]
PHST- 2007/07/10 00:00 [revised]
PHST- 2007/07/12 00:00 [accepted]
PHST- 2007/11/14 09:00 [pubmed]
PHST- 2008/03/07 09:00 [medline]
PHST- 2007/11/14 09:00 [entrez]
AID - S0969-8051(07)00187-4 [pii]
AID - 10.1016/j.nucmedbio.2007.07.007 [doi]
PST - ppublish
SO  - Nucl Med Biol. 2007 Nov;34(8):955-60. doi: 10.1016/j.nucmedbio.2007.07.007. Epub 
      2007 Sep 19.